“The purpose is to turn up the heat and get resources to develop these more natural options that could be very important.”
By Jack Gorsline, Psychedelic State(s) of America
As cannabis rescheduling efforts under the Trump administration draw closer to finalization and Food and Drug Administration (FDA) approval of the first wave of synthetic psychedelic drugs looms large in the near future, a new bill introduced in the U.S. House of Representatives aims to stimulate private investment in plant-based medicines by offering a 12-year market exclusivity period for newly approved botanical drugs.
Introduced on August 27 by Reps. Lauren Boebert (R-CO) and Derrick Van Orden (R-WI), the Advancing Botanical Drug Development Act of 2026, or H.R. 10150, seeks to amend the Federal Food, Drug and Cosmetic Act.
Under the proposed legislation, FDA would be prohibited from approving generic or hybrid applications that reference a newly approved botanical drug during its 12-year exclusivity window. Supporters of the bill argue this extended period is necessary to overcome the unique scientific, manufacturing and regulatory challenges that currently discourage private investment under standard intellectual property laws.
Joel Stanley, CEO of AJNA Biosciences noted in an interview with Psychedelic State(s) of America that while the FDA created a regulatory pathway for
Read full article on Marijuana Moment
